2025
Mediators of Racial Inequities in Non‐Small Cell Lung Cancer Care
Hamid S, Lee D, Herrin J, Yu J, Pollack C, Dean L, Gaddy J, Oladele C, Feder S, Canavan M, Nunez-Smith M, Soulos P, Gross C. Mediators of Racial Inequities in Non‐Small Cell Lung Cancer Care. Cancer Medicine 2025, 14: e70757. PMID: 40052387, DOI: 10.1002/cam4.70757.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancer carePhase of careSocioeconomic statusNon-small cell lung cancerIndividual-level socioeconomic statusNeighborhood-level socioeconomic statusMedicare-Medicaid dual eligibilityWhite patientsHealth care accessLung cancer careNon-Hispanic blacksIndirect effects of mediatorsDiagnosis stageStage-appropriate treatmentTwo-year survivalCancer careCare accessEffects of raceOptimal careDual eligiblesCareStructural racismRacial inequalityBlack patientsInadequate evaluationRacial and ethnic disparities in conversion to mastectomy following lumpectomy
Khubchandani J, KC M, Dey P, Proussaloglou E, Valero M, Berger E, Park T, Gross C, Butler P, Fayanju O, Winer E, Golshan M, Greenup R. Racial and ethnic disparities in conversion to mastectomy following lumpectomy. Breast Cancer Research And Treatment 2025, 211: 99-110. PMID: 39937397, DOI: 10.1007/s10549-025-07625-6.Peer-Reviewed Original ResearchConceptsConversion to mastectomyNeoadjuvant chemotherapyBreast conservationStage 0-III breast cancerWhite womenBreast cancerBlack womenBreast cancer careNational Cancer DatabaseMultivariate logistic regression modelEvaluate contemporary trendsLogistic regression modelsCancer careImprove disparitiesEthnic disparitiesDiagnosis yearInitial lumpectomySocio-demographicCancer DatabaseClinical factorsMastectomyLumpectomySurgeryResultsThe studyTreatment sequence
2023
Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma
Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum 2023, 7: pkad036. PMID: 37202354, PMCID: PMC10276895, DOI: 10.1093/jncics/pkad036.Peer-Reviewed Original ResearchConceptsOral anticancer agentsTherapy utilizationMedicare beneficiariesNon-Hispanic white raceMetastatic renal cell carcinomaNon-Hispanic black raceOlder US patientsUS Medicare beneficiariesRenal cell carcinomaLogistic regression modelsTherapy receiptMultivariable adjustmentSystemic therapyMale sexUS patientsCell carcinomaStudy criteriaBlack raceFemale sexPatient raceWhite raceImmunotherapyOutcomes persistSexPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply